Posts tagged Immune Biosolutions
Appointment of a new Director to the Board of Directors of Immune Biosolutions Inc.

We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco. The arrival of Mr. Franco is part of the company’s development strategy. With over 32 years of experience in the pharmaceutical industry, research, marketing, sales, and business development in several therapeutic areas, both domestically and internationally, “He will certainly bring a unique strategic perspective of the industry and a vision focused on value creation to the Board,” says Luc Paquet, CEO of the company.

Read More
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy with an ongoing multisite phase 1 and 2 clinical program for the treatment of symptomatic SARS-CoV-2 patients.

Read More
Appointment of Luc Paquet as Chief Executive Officer - Immune Biosolutions enters into a new chapter of its growth

Immune Biosolutions Inc. is consolidating its biopharmaceutical transition, following the accelerated development of its activities. The company will focus its activities towards the discovery and development of immunotherapies for infectious diseases, inflammation and cancer. To propel Immune Biosolutions' growth in this new phase, the company is pleased to announce the appointment of Mr. Luc Paquet as Chief Executive Officer.

Read More
Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants

SHERBROOKE, Québec (March 16, 2021)—Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.

Read More